{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:21:43Z","timestamp":1784154103462,"version":"3.55.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background  Up to now, it is unclear whether different medicinal\n                        cannabis (MC) strains are differently efficacious across different\n                    medical conditions. In this study, the effectiveness of different MC strains was\n                    compared depending on the disease to be treated.<\/jats:p><jats:p>\n          Methods  This was an online survey conducted in Germany between June 2020\n                    and August 2020. Patients were allowed to participate only if they received a\n                        cannabis-based treatment from pharmacies in the form of\n                        cannabis flowers prescribed by a physician.<\/jats:p><jats:p>\n          Results  The survey was completed by n=1,028 participants. Most\n                    participants (58%) have used MC for more than 1 year, on average, 5.9 different\n                    strains. Bedrocan (pure tetrahydrocannabinol to pure cannabidiol\n                    [THC:CBD]=22:&lt;1) was the most frequently prescribed strain, followed by\n                        Bakerstreet (THC:CBD=19:&lt;1) and Pedanios 22\/1\n                    (THC:CBD=22:1). The most frequent conditions MC was prescribed for were\n                    different pain disorders, psychiatric and neurological diseases, and\n                    gastrointestinal symptoms. Overall, the mean patient-reported effectiveness was\n                    80.1% (range, 0\u2013100%). A regression model revealed no association between the\n                    patient-reported effectiveness and the variety. Furthermore, no influence of the\n                    disease on the choice of the MC strain was detected. On average, 2.1 side\n                    effects were reported (most commonly dry mouth (19.5%), increased appetite\n                    (17.1%), and tiredness (13.0%)). However, 29% of participants did not report any\n                    side effects. Only 398 participants (38.7%) indicated that costs for MC were\n                    covered by their health insurance.<\/jats:p><jats:p>\n          Conclusions  Patients self-reported very good efficacy and tolerability of\n                    MC. There was no evidence suggesting that specific MC strains are superior\n                    depending on the disease to be treated.<\/jats:p>","DOI":"10.1055\/a-2261-2269","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:08:48Z","timestamp":1710288528000},"page":"133-140","source":"Crossref","is-referenced-by-count":12,"title":["Medicinal Use of Different Cannabis Strains: Results from a Large\n                    Prospective Survey in Germany"],"prefix":"10.1055","volume":"57","author":[{"given":"Natalia","family":"Szejko","sequence":"additional","affiliation":[{"name":"Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover\n                    Medical School, Hannover, Germany"},{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary,\n                    Canada"},{"name":"Department of Bioethics, Medical University of Warsaw, Warsaw,\n                    Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Becher","sequence":"additional","affiliation":[{"name":"Department of Sex- and Gender-specific Medicine, University of\n                    Bielefeld, Bielefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heimann","sequence":"additional","affiliation":[{"name":"Cannabis-Apotheke.de, Apotheke LUX99, H\u00fcrth,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franjo","family":"Grotenhermen","sequence":"additional","affiliation":[{"name":"International Association for Cannabinoid Medicines, Steinheim,\n                    Germany"},{"name":"Center for Cannabis Medicine, Steinheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten R.","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[{"name":"Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover\n                    Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000521683","article-title":"Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based\n                    pharmaceuticals","volume":"107","author":"C A Legare","year":"2022","journal-title":"Pharmacology."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/02791072.2017.1390179","article-title":"Mother of berries, ACDC, or chocolope?: Examination of the strains used by\n                    medical cannabis patients in New England","volume":"50","author":"B J Piper","year":"2018","journal-title":"J Psychoactive Drugs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/JCP.0000000000000129","article-title":"Therapeutic satisfaction and subjective effects of different strains of\n                    pharmaceutical-grade cannabis","volume":"34","author":"T M Brunt","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref6","first-page":"23","article-title":"The use of cannabinoids for insomnia in daily life: Naturalistic study","volume":"14","author":"N Kuhathasan","year":"2021","journal-title":"J Med Internet Res"},{"key":"ref7","first-page":"375","article-title":"Efficacy of different varieties of medical cannabis in relieving\n                    symptoms","volume":"10","author":"B A Wan","year":"2017","journal-title":"J Pain Manage"},{"key":"ref8","first-page":"9","article-title":"The Association between cannabis product characteristics and symptom\n                    relief","volume":"15","author":"S S Stith","year":"2019","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/JCP.0000000000000129","article-title":"Therapeutic satisfaction and subjective effects of different strains of\n                    pharmaceutical-grade cannabis","volume":"34","author":"T M Brunt","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejim.2018.01.019","article-title":"Epidemiological characteristics, safety and efficacy of medical cannabis\n                    in the elderly","volume":"49","author":"R Abuhasira","year":"2018","journal-title":"Eur J Intern Med [Internet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000512342","article-title":"Demographics, perceptions, and use of medical marijuana among patients in\n                    Florida","volume":"4","author":"M S Rosenthal","year":"2021","journal-title":"Med Cannabis Cannabinoids"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/jcm9041166","article-title":"Characteristics of older adults who were early adopters of medical\n                        cannabis in the Florida Medical Marijuana Use Registry","volume":"9","author":"J D Brown","year":"2020","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/02791072.2011.587700","article-title":"Who are medical marijuana patients? Population characteristics from nine\n                    California assessment clinics","volume":"43","author":"C Reinarman","year":"2011","journal-title":"J Psychoactive Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7517-4-1","article-title":"Long term marijuana users seeking medical cannabis in California\n                    (2001-2007): Demographics, social characteristics, patterns of cannabis\n                    and other drug use of 4117 applicants","volume":"4","author":"T J O\u2019Connell","year":"2007","journal-title":"Harm Reduct J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jpain.2019.05.009","article-title":"Cannabis use preferences and decision-making among a cross-sectional\n                    cohort of medical cannabis patients with chronic pain","volume":"20","author":"K F Boehnke","year":"2019","journal-title":"J Pain"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.addbeh.2015.06.032","article-title":"Cannabis species and cannabinoid concentration preference among\n                    sleep-disturbed medicinal cannabis users","volume":"50","author":"K A Belendiuk","year":"2015","journal-title":"Addict Behav"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-016-0119-9","article-title":"Medical cannabis use in Canada: Vapourization and modes of delivery","volume":"13","author":"S Shiplo","year":"2016","journal-title":"Harm Reduct J"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.socscimed.2019.06.005","article-title":"Patient-reported use of medical cannabis for pain, anxiety, and\n                    depression symptoms: Systematic review and meta-analysis","volume":"233","author":"J D Kosiba","year":"2019","journal-title":"Soc Sci Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"827849","DOI":"10.3389\/fmed.2022.827849","article-title":"Adherence, safety, and effectiveness of medical cannabis and\n                    epidemiological characteristics of the patient population: A prospective\n                    study","volume":"9","author":"L Bar-Lev Schleider","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: A systematic review and meta-analysis","volume":"313","author":"P F Whiting","year":"2015","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00431-021-04202-z","article-title":"Use and caregiver-reported efficacy of medical cannabis in children and\n                    adolescents in Switzerland","volume":"181","author":"K Z\u00fcrcher","year":"2022","journal-title":"Eur J Pediatr"},{"key":"ref22","first-page":"942","article-title":"Self-reported effects of cannabis on ADHD symptoms, ADHD medication side\n                    effects, and ADHD-related executive dysfunction","volume":"26","author":"A Stueber","year":"2021"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jpsychires.2022.11.029","article-title":"Cannabis use in attention \u2013 deficit\/hyperactivity disorder (ADHD): A\n                    scoping review","volume":"157","author":"A P Francisco","year":"2023","journal-title":"J Psychiatr Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jpsychires.2021.05.044","article-title":"Potential therapeutic benefits of cannabinoid products in adult psychiatric\n                    disorders: A systematic review and meta-analysis of randomised controlled\n                    trials","volume":"140","author":"K A McKee","year":"2021","journal-title":"J Psychiatr Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.7326\/M21-4520","article-title":"Cannabis-based products for chronic pain: A systematic review","volume":"175","author":"M S McDonagh","year":"2022","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/bs.apha.2017.03.004","article-title":"Cannabis pharmacology: The usual suspects and a few promising l eads","volume":"80","author":"E B Russo","year":"2017","journal-title":"Adv Pharmacol"},{"key":"ref27","first-page":"1095","volume-title":"Prevalence and correlates of cannabis use disorder among Australians\n                    using cannabis products to treat a medical condition","author":"L Mills","year":"2022"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"107667","DOI":"10.1016\/j.addbeh.2023.107667","article-title":"Prevalence of cannabis use disorder among individuals using medical\n                        cannabis at admission to inpatient treatment for substance use\n                    disorders","volume":"142","author":"NS G Marie","year":"2023","journal-title":"Addict Behav"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2261-2269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:58:32Z","timestamp":1730804312000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2261-2269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":26,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,5,7]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2261-2269","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}